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Abstract
Background: Several familial Alzheimer disease (FAD) mutations within the transmembrane region of the amyloid
precursor protein (APP) increase the Ab42/40 ratio without increasing total Ab production. In the present study, we
analyzed the impact of FAD mutations and g-secretase modulators (GSMs) that alter the Ab42/40 ratio on APP
C-terminus (CT) positioning relative to the membrane, reasoning that changes in the alignment of the APP
intramembranous domain and presenilin 1 (PS1) may impact the PS1/g-secretase cleavage site on APP.
Results: By using a Förster resonance energy transfer (FRET)-based technique, fluorescent lifetime imaging
microscopy (FLIM), we show that Ab42/40 ratio-modulating factors which target either APP substrate or PS1/g-
secretase affect proximity of the APP-CT to the membrane and change PS1 conformation.
Conclusions: Thus, we propose that there is a reciprocal relationship between APP-CT positioning relative to the
membrane and PS1 conformation, suggesting that factors that modulate either APP positioning in the membrane
or PS1 conformation could be exploited therapeutically.
Background
g-Secretase is responsible for cleavage of a number of
type I membrane proteins, including amyloid precursor
protein (APP) and Notch, and is comprised of presenilin
1 or 2, Aph1, Pen2 and Nicastrin [1-5]. Proteolytic pro-
cessing of APP by b-a n dg-secretases results in produc-
tion of amyloid b (Ab) peptides. The major Ab species
are 40 and 42 amino acid long peptides, the latter of
which is recognized as the more toxic species involved
in Alzheimer’s disease (AD) pathogenesis [2,6,7]. Factors
that modulate the Ab42/40 ratio can be classified into at
least two categories; 1) substrate-targeting manipula-
tions, such as FAD-linked mutations within the intra-
membranous region of the APP substrate [8,9], and 2)
g-secretase-targeting modifications, such as FAD-linked
PS1 mutations [10-12], Pen-2 N-terminus modification
[13] or expression of different Aph1 isoform [14]. In
addition, treatment with pharmacological agents, g-
secretase modulators (GSMs), could alter the Ab42/40
ratio [15-17]. However, there is a controversy whether
the primary target of these compounds is APP substrate
[18-20], or PS1/g-secretase [21-25].
Using Förster resonance energy transfer (FRET)/fluor-
escent lifetime imaging microscopy (FLIM) technique,
we have previously demonstrated that PS1, a catalytic
site of g-secretase, could exist in a “closed” (close proxi-
mity between the PS1 N-terminus, C-terminus, and a
large cytoplasmic loop domain) and “open” (longer dis-
tance between them) conformations [26-28]. Although
the detailed molecular mechanism responsible for differ-
ent PS1 conformational states, and underlying the preci-
sion of APP cleavage by PS1/g-secretase is currently
unknown, we found that the “closed” conformation of
PS1 is consistently linked to a higher Ab42/40 ratio,
whereas the “open” conformation is associated with a
lower Ab42/40 ratio [26-28].
Notably, in addition to manipulations directly targeting
components of the g-secretase complex, mutations within
the transmembrane region of the APP substrate have
been shown to induce changes in the PS1 conformation.
For example, APP with FAD-linked V717I or I716F
mutations that increase the Ab42/40 ratio seem to associ-
ate with the PS1/g-secretase earlier in the secretory path-
way, alter the alignment of APP with PS1, and shift PS1
into a “close” NT and CT proximity conformation [29].
* Correspondence: oberezovska@partners.org
1Alzheimer Research Unit, MassGeneral Institute for Neurodegenerative
Diseases, Massachusetts General Hospital, Charlestown, MA 02129, USA
Full list of author information is available at the end of the article
Uemura et al. Molecular Neurodegeneration 2011, 6:15
http://www.molecularneurodegeneration.com/content/6/1/15
© 2011 Uemura et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Conversely, the APP V715F substitution, which dramati-
cally decreases the Ab40 and Ab42 while increasing Ab38
levels, induced a structural rearrangements in PS1 remi-
n i s c e n to ft h a to b s e r v e da f t e rt h et r e a t m e n tw i t hA b42
-lowering non-steroidal anti-inflammatory drugs ("open”
conformation) [30].
Based on these findings, we hypothesized that APP-
targeting manipulations may alter conformation of the
APP molecule or it’s positioning within the plane of the
membrane. This alteration may change APP substrate
presentation to the PS1/g-secretase, and consequently
induce a shift in PS1 conformation. Since previous
structural analysis predicts that the APP cytoplasmic
domain can associate with the membrane and alter its
positioning in response to various stimuli [31], in the
current study we analyzed proximity between the mem-
brane and APP-CT as readout of APP transmembrane
positioning. Thus, to better understand the relationship
between APP CT transmembrane positioning, PS1/g-
secretase conformation, and the Ab42/40 ratio, we asked
whether APP-CT proximity to the membrane correlates
with the Ab42/40 ratio and can be affected by the PS1
conformational change. The FLIM assay was utilized to
monitor relative distance between the two fluorophores
labelling membrane and APP-CT in intact cells. We
found that FAD mutations within the APP transmem-
brane domain, that raise the Ab42/40 ratio, increase
proximity of the APP-CT to the membrane. Interest-
ingly, treatment of cells with GSMs, which are known to
modify the Ab42/40 ratio and induce PS1 conformational
change [24,26,28], led to altered APP-CT and membrane
p r o x i m i t yo n l yi nt h ep r e s e n c eo fP S 1 / g-secretase. Sur-
prisingly, we found that Ab42/40 ratio-raising FAD-linked
mutations in PS1 also affect the positioning of APP rela-
tive to the membrane in a manner similar to that of the
FAD-linked APP mutations. These results suggest a
reciprocal relationship between conformation of the
APP-CT and/or its orientation relative to the membrane
and PS1 conformation. Thus, factors that modulate
either APP positioning or PS1 conformation could be
exploited therapeutically to correct pathogenic Ab42/40
ratio, and thus prevent or slow down progression of AD.
Results
The Ab42/40 ratio-raising APP mutations increase the
proximity between APP-CT and the membrane
First, we measured the effect of V717I, V717K or I716F
mutations located in the transmembrane domain of
APP on the Ab42/40 ratio in CHO cells transiently trans-
fected with the mutant APP constructs. As reported pre-
viously [8,9], the amount of Ab42 was increased while
the amount of the Ab40 was decreased in the condi-
tioned medium of V717I and I716F APP expressing
cells, leading to a significantly elevated Ab42/40 ratio
(Figure 1A). By contrast, artificial V717K APP mutation
[32] significantly lowered the Ab42/40 ratio.
To determine whether these APP mutations affect
APP-CT proximity to the membrane, APP-CT-RFP
(wild-type or mutant) was co-transfected with either
myrGFP or EGFP into APP/APLP2 dKO cells, and the
lifetime of GFP donor was measured by FLIM. MyrGFP
has a myristoylation sequence that restricts expression
of GFP to the membrane [33]. In cells transfected with
the myrGFP and wild-type APP-RFP, the lifetime of
donor GFP was shortened, compared to that in the
myrGFP only expressing cells. This indicates energy
transfer from myrGFP to RFP, and close proximity
between the APP-CT and membrane. However, in cells
transfected with the EGFP without myristoylation signal,
the donor lifetime did not change significantly by co-
expression with the APP-RFP (Figure 1B, C), confirming
specificity of the FRET signal in the former, and close
proximity of the APP CT to the membrane.
Interestingly, cells transfected with APP-RFP mutants
that yield high Ab42/40 ratio (V717I and I716F) showed
shorter myrGFP donor lifetime, compared to that in
cells transfected with the wild-type APP-RFP (Figure
1C), indicating increased proximity between mutant
APP-CT and the membrane. As expected, APP-RFP
V717I mutant did not shorten the lifetime of EGFP
without myristoylation signal, confirming that the
observed shortening of the myrGFP lifetime was specifi-
cally caused by the closer proximity of the RFP acceptor
at V717I and I716F APP C-termini to the membrane.
Conversely, myrGFP donor lifetime was significantly
longer in cells expressing Ab42/40 ratio-lowering V717K
APP-RFP mutant, compared to that in the wild-type
APP-RFP cells (Figure 1C). The level of expression for
different APP mutants is shown in Additional file 1, Fig-
ure S1. Please note, APP I716F and V717K mutants are
expressed at comparable levels, however, these muta-
tions affect APP-RFP proximity to the membrane in an
opposite fashion, as detected by the FLIM assay. More-
over, additional tests were performed to demonstrate
that the levels of APP-RFP (Additional file 1, Figure S2)
or PS1 (Additional file 1, Figure S3) expression do not
affect the myrGFP donor fluorophore lifetime in the
FLIM assay. This further confirms that it is the Ab42/40
ratio altering mutations, and not the level of expression,
that affect APP CT proximity relative to the membrane.
We used a two-exponential model of the lifetime ana-
lysis for the measurement of myrGFP and APP-CT
proximity (see Methods and [24,27]). First, the baseline
myrGFP lifetime (t1, no FRET) is established in the
absence of an acceptor fluorophore. When myrGFP
(membrane) and APP-RFP proximity is analysed, the
population with a longer lifetime (no FRET) is “fixed”,
i.e. excluded from the lifetime analysis, and a shorter
Uemura et al. Molecular Neurodegeneration 2011, 6:15
http://www.molecularneurodegeneration.com/content/6/1/15
Page 2 of 10Figure 1 The Ab42/40 ratio-modulating APP mutations induce changes in APP positioning relative to the membrane .A )E L I S A
detection of the human Ab40 and Ab42 in conditioned media of the cells transiently transfected with human APP-RFP constructs with
designated mutations. The amount of each Ab species was normalized to that obtained from the cells expressing wild-type APP-RFP (Ab40 ≈70
pMol/L, Ab42 ≈1 pMol/L). Three independent experiments were performed. (mean ± SD; *p < 0.001 vs. wild-type APP-RFP, ANOVA, n: number of
wells in the representative experiment shown). B) FLIM analysis of the proximity between APP-CT RFP and myrGFP labeled membrane. The
pseudo-colour images show distribution of the EGFP and myrGFP donor fluorophore lifetimes in the presence (bottom) or absence (top) of the
RFP acceptor fluorophore fused to the wild-type APP-CT. Only cells transfected with myrGFP as a donor fluorophore showed lifetime shortening
(red and yellow pixels) in the presence of APP-RFP, with the shortest lifetime at the cell periphery. Scale bar: 10 μm. Colorimetric scale shows
GFP fluorophore lifetime in picoseconds. C) Quantitative FLIM analysis of the GFP lifetimes in APP/APLP2 dKO cells expressing wild-type and
mutant APP-RFP constructs. In cells transfected with the EGFP as a donor fluorophore (grey bars), the donor lifetime did not change significantly
in the presence of either wild-type or V717I APP-RFP. In cells transfected with myrGFP as a donor (black bars), the donor lifetime was
significantly shortened in the presence of RFP acceptor at the APP CT. FAD-linked APP mutations (V717I and I716F) significantly shortened,
whereas V717K APP mutation significantly increased the lifetime of myrGFP donor, compared to that of the wild-type APP (mean ± SD; *p <
0.001, **p < 0.01, ANOVA). Data from one of the three independent experiments is shown; n = cell number. D) CHO cells were transfected with
APP-GFP to serve as a donor fluorophore (green) in the FLIM assay. Plasma membrane was stained with CM-DiI to serve as an acceptor
fluorophore (red). Merged image shows that APP signal is outlined by red membrane. Scale bar; 10 μm. E) The graph shows average lifetime of
GFP donor fluorophore in CHO cells from (D). The lifetime of GFP donor was shortened in cells with CM-DiI membrane staining. In the presence
of I716F and V717I mutations, the GFP lifetime was significantly shorter than that in wild-type APP-GFP transfected cells (mean ± SD; *p < 0.01,
ANOVA). Three independent experiments were performed (n: total cell number).
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recorded. Thus, parts of the myrGFP labelled membrane
that do not contain RFP-labeled APP (or most of the
APP molecules not interacting with PS1/g-secretase, see
bellow) have been excluded from the analysis and com-
parisons between different experimental conditions.
To verify the above finding, we used an alternative
strategy by reversing the donor and acceptor fluoro-
phores. GFP fused to the APP-CT served as a donor
fluorophore, and CM-DiI was used to stain the mem-
brane, and served as a FRET acceptor (Figure 1D). As
expected, in the presence of CM-DiI staining, the life-
time of GFP was significantly shortened, indicating
energy transfer from the GFP to DiI, and close proxi-
mity of the APP-CT to the membrane (Figure 1E). Pre-
sence of the Ab42 -raising APP mutations led to a
further shortening of the APP-GFP lifetime (Figure 1E),
confirming that APP mutations caused a shift in the
APP-CT orientation relative to the membrane.
g-Secretase modulators (GSMs) cause a shift in the APP
positioning within the membrane
It has been reported recently [18,19] that Ab42/40 ratio-
modulating GSMs could directly bind to the APP sub-
strate. Thus, we tested whether GSMs affect the Ab42/40
ratio by altering APP membrane positioning. For this,
APP/APLP2 dKO cells co-transfected with myrGFP and
wild-type APP-RFP were treated with either Ab42-raising
(fenofibrate, celecoxib) or Ab42-lowering (ibuprofen,
indomethacin, flurbiprofen) GSMs. We found that fenofi-
brate and celecoxib treatment significantly decreased the
lifetime of myrGFP donor, compared to the vehicle con-
trol treatment, indicating that they changed positioning
of the APP-CT relative to the membrane in the same
direction as Ab42/40 ratio-raising APP FAD mutations
(Figure 2A). Conversely, treatment with Ab42-
lowering GSMs increased the donor lifetime (Figure 2A).
T h e s ef i n d i n g ss u p p o r tt h ei d e at h a tc h a n g ei nt h ep o s i -
tioning of APP-CT to the membrane reflects a change in
the Ab42/40 ratio, with shorter distance between the APP-
CT and membrane correlating with a higher, and longer
distance with a lower Ab42/40 ratio.
Our previous studies showed that fenofibrate and ibu-
profen could also allosterically modify PS1 conforma-
tion. To demonstrate whether there is any interplay
between the APP-CT position and PS1 conformation,
we asked whether GSMs could affect APP-CT orienta-
tion in the absence of PS1/g-secretase. To answer this
question, PS1/2 dKO cells co-transfected with myrGFP
and wild-type APP-RFP were treated with either ibupro-
fen or fenofibrate. We found that treatment with neither
one of the GSMs affect the lifetime of myrGFP donor in
the absence of PS1/2 (Figure 2B). Moreover, our data
indicate that APP-CT locates far from the membrane so
that the distance cannot support the energy transfer
from myrGFP to RFP on the APP-CT in the absence of
presenilins.
To establish whether PS1/g-secretase presence and/or
interaction with the APP substrate are needed to change
positioning of APP-CT relative to the membrane, we
used the previously characterized helical peptide (HP)
g-secretase inhibitor, which docks to the substrate-bind-
ing site on g-secretase and prevents binding of APP to
the PS1/g-secretase [34]. Wild-type APP-RFP was trans-
fected into either PS1/2 dKO cells or PS1/2 dKO cells
reconstituted by stable expression of the wild-type PS1
(PS1/2 dKO + wild-type PS1 cells). Once again, the
expression of APP-RFP did not alter the lifetime of
donor myrGFP in PS1/2 dKO cells, indicating that APP-
CT and the membrane are not close enough to support
FRET in the absence of presenilins. On the contrary, the
donor lifetime was significantly shortened in PS1/2 dKO +
wild-type PS1 cells, indicating that APP-CT proximity to
the membrane changes in the presence of PS1. When APP
docking to PS1/g-secretase was inhibited by HP treatment
in PS1/2 dKO + wild-type PS1 cells, we observed a signifi-
cant increase in the myrGFP donor lifetime, confirming
that APP-PS1 interaction affects the positioning of
APP-CT (Figure 2C). As mentioned above, the two-
exponential FLIM analysis of APP-PS1 interactions, which
monitors only those APP molecules that do interact with
PS1/g-secretase, leads to increased sensitivity of the assay
to “presenilin effects” on APP-CT orientation towards the
membrane.
Similar results were obtained after HP treatment of
the APP/APLP2 dKO cells transfected with APP-RFP
and expressing wild-type PS1 on endogenous levels
(Additional file 1, Figure S4), indicating that APP bind-
ing/interaction with the PS1/g-secretase rearranges the
APP-CT positioning.
FAD-linked PS1 mutations alter APP-CT positioning
relative to the membrane
We have previously found that FAD-linked PS1 mutants
modify PS1 conformation, and as a result alter an align-
ment of PS1/g-secretase with the APP substrate [27]. To
test whether this may lead to a change in the position-
ing of APP-CT relative to the membrane, we monitored
proximity between the membrane and APP-CT in PS1/2
dKO cell lines, reconstituted by stable expression of
either wild-type PS1 or PS1 with FAD-linked mutations
(L166P, Delta9, A246E). Indeed, we found that expres-
sion of each FAD-linked PS1 mutation caused a change
in the APP-CT positioning (shortening of the GFP
donor lifetime) (Figure 3A), similar to that caused by
the FAD APP mutations.
To confirm this finding, PS1/2 dKO cells were transi-
ently co-transfected with either wild-type PS1, FAD-linked
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Page 4 of 10Figure 2 FLIM analysis of the effect of GSMs and HP on APP-CT positioning relative to the membrane . A) APP/APLP2 dKO cells co-
transfected with myrGFP and wild-type APP-RFP were treated with vehicle control, fenofibrate (FF), celecoxib (cele), ibuprofen (ibu),
indomethacin (indo), or flurbiprofen (flurbi). The donor lifetime shortened in cells treated with FF and cele, and increased in cells treated with
ibu, indo and flurbi, reflecting increased and decreased proximity between the APP-CT and membrane, respectively, compared to that in cells
treated with the DMSO vehicle. mean ± SD; *p < 0.05; **p < 0.001, ANOVA; n = 42-84 cells analyzed per condition in three independent
experiments. B) PS1/2 dKO cells were co-transfected with myrGFP and APP-RFP, and treated with fenofibrate or ibuprofen. Neither ibuprofen nor
fenofibrate treatment significantly changed the myrGFP lifetime in PS1/2 dKO cells. C) PS1/2 dKO cells (green bar) and PS1/2 dKO + wild-type
PS1 cells (black bars) co-transfected with myrGFP and APP-RFP were treated with either DMSO or HP to prevent APP-PS1 interactions. Three to
five independent experiments were performed. Data from a representative experiment is shown. n: number of cells analyzed in the experiment
(*p < 0.01; **p < 0.05; n.s. - not significant; ANOVA).
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Figure 3 FAD-linked PS1 mutations alter APP CT positioning . FLIM analysis of the myrGFP lifetime in PS1/2 dKO cells stably (A) or
transiently (B) expressing wild-type or mutant PS1. The cells were co-transfected with myrGFP and wild-type APP-RFP as a FRET pair, and the
proximity between myrGFP (membrane) and RFP (APP-CT) was monitored. All FAD-linked PS1 mutations significantly shortened myrGFP lifetime
compared to that in the wild-type PS1 expressing cells. The expression of E318G PS1 caused no significant difference in the donor lifetime.
Three independent experiments were performed. Data from a representative experiment is shown (n: number of cells; mean ± SD;*p < 0.05;
**p < 0.01; ANOVA).
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Page 5 of 10G384A PS1, or non-pathogenic E318G PS1 polymorphism
together with the myrGFP and wild-type APP-RFP. As
expected, expression of the G384A mutant PS1 shortened
the lifetime of myrGFP, compared to that of the wild-type
PS1. On the other hand, expression of the E318G
PS1 polymorphism had no effect on the myrGFP lifetime
(Figure 3B), indicating that FAD-linked mutations, but
not a benign polymorphism, alter APP-CT orientation
relative to the membrane. Thus, these findings demon-
strate that altered conformation of the FAD mutant PS1
and resulting “misalignment” with the APP substrate that
leads to increased Ab42/40 ratio, also changes positioning
of the APP-CT.
Discussion
The cytoplasmic domain of APP is believed to function
in multiple signalling pathways ranging from apoptosis
to gene transcription regulation [35]. APP intracellular
domain has been shown to interact with various mole-
cules and contribute to axonal transport [36], neurite
outgrowth and arborization [37], and signalling events
in the cell [38,39]. Thus, alterations in APP-CT struc-
ture in pathological settings could ultimately interfere
with these events and accelerate neuropathological
changes. A potential relationship between the APP-CT
conformation and Ab production has been suggested.
For example, structural studies of the APP-CT have
demonstrated that although APP-CT does not adopt a
stable folded conformation, it has a transient preordered
structure, whose conformation can be altered by phos-
phorylation [40,41]. In addition, a recent structural
model predicts that APP-CT might be associated with
the membrane, and suggests that APP-CT association
with and dissociation from the membrane might regu-
late interactions of APP with various proteins [31], and
could contribute to an altered Ab42/40 ratio. A new
g-secretase activating protein has been recently
described that interacts with both PS1 and APP C-term-
inal fragment (but not with the Notch substrate), affects
Ab production, and may alter the structural relationship
between g-secretase and APP CT [42].
A model in which there is successive release of tri-
peptides has been proposed for differential production
of the Ab40 and Ab42 species [43,44]. According to this
model, Ab49 produced by PS1/g-secretase dependent
ε-cleavage of APP at the membrane-cytosol interface is
converted to Ab40 after successive release of tri-peptides,
whereas initial ε-cleavage of APP at the Ab48 site is con-
verted to the Ab42. In the present study, we employed
the FLIM assay in intact cells to demonstrate that APP-
CT positioning relative to the membrane, or a confor-
mational change of the APP/C99 cytoplasmic domain,
correlates with changes in the Ab42/40 ratio. We found
that Ab42/40 ratio-raising mutations in PS1 or in the
APP transmembrane region altered APP positioning
w i t h i nt h em e m b r a n eb yb r i n g i n gt h eA P PC - t e r m i n u s
closer to the membrane. Thus, a conformational change
of the APP cytoplasmic domain, which we observed in
the current study, may affect the initial APP cleavage at
the ε-site by altering APP substrate presentation to PS1/
g-secretase at the membrane-cytosol interface.
Interestingly, we found that PS1/g-secretase itself has a
profound effect on APP-CT positioning relative to the
membrane. First, our data indicate that in the absence of
PS1/g-secretase or when APP-PS1/g-secretase interaction
is inhibited by HP treatment, FRET between APP-CT-RFP
and myrGFP-membrane is absent, suggesting that the dis-
tal part of the APP-CT is located relatively far away from
the membrane. Surprisingly, it appears as if interaction of
APP with the PS1/g-secretase affects the orientation of
APP-CT by bringing it into close proximity to the mem-
brane (FRET present). Moreover, interactions with FAD
mutant PS1/g-secretase further change the positioning of
the APP-CT to obtain an even closer proximity relative to
the membrane. Although the precise mechanism of how
mutations in PS1 affect APP positioning relative to the
membrane is unknown, it is possible that in the process of
APP substrate alignment with the topographically altered
mutant g-secretase active site, changes in the APP-CT
membrane proximity occur. This is in agreement with a
cross-linking experiment demonstrating that aggressive
FAD-linked PS1 mutations cause alterations in topography
of the g-secretase active site [45].
GSMs have been shown to affect both PS1 conformation
[13,24,26-28], as well as APP positioning in the membrane
(current study). There remains an uncertainty over the pri-
mary target of GSMs, with some studies showing that
GSMs target g-secretase, either PS1 itself or other compo-
nents, such as Pen2, [21,22,42], whereas others propose that
GSMs directly bind to the APP substrate [18-20]. In our
current study, we did not observe any effect of GSMs on
APP-CT positioning in the absence of PS1 and PS2. How-
ever, we could not exclude the possibility that GSMs bind-
i n gm a yh a v eas u b t l ee f f e c tw i t h i nt h er a n g eo fn o n -
FRETing distance (>10 nm) from the membrane in PS1/2
dKO cells, thus rendering the APP-CT positioning change
undetectable by our current method. It is also possible that
some GSMs could still bind to APP CTF in the absence of
presenilins but it requires the complex formation for the
conformational shift to occur. We have recently reported
that the modulatory effect of GSMs is implemented
through the “allosteric site” located within the g-secretase
complex itself, although substrate docking to g-secretase is
needed to allow GSM access to this site [24]. Thus, the
most likely scenario is that these GSMs primarily target
PS1/g-secretase or the PS1/APP interface, and the change
in APP positioning within the membrane is a secondary
response to the change of PS1 conformation.
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In summary, our data demonstrate that interaction of
the APP substrate with PS1/g-secretase changes APP CT
positioning relative to the membrane. Moreover, both
APP-targeting and PS1-targeting manipulations that
change the Ab42/40 ratio can affect APP orientation rela-
tive to the membrane as well as PS1 conformation, indi-
cating that APP-CT positioning and PS1 conformation
are tightly interconnected, and are in a reciprocal rela-
tionship (Figure 4). Thus, exploring factors affecting
PS1 as well as APP conformation would render more
insights into the AD pathogenesis, and may provide new
information about potential therapeutic targets.
Methods
Cell Lines and Pharmacological treatments
PS1/PS2 double knockout (PS1/2 dKO) mouse embryo-
nic fibroblasts (MEFs), and PS1/2 dKO cells reconsti-
tuted by stable expression of wild-type or FAD-linked
PS1 (L166P, Delta9 and A246E) were a generous gift
from Dr. Bart Destrooper [46]. APP/APLP2 dko MEFs
were generous a gift from Dr. Koo. Chinese Hamster
Ovary (CHO) cells were obtained from ATCC. Cells
were cultured with Opti-MEM (Invitrogen) supplemen-
ted with 5% fetal bovine serum. The cells plated into
four-chamber slides were transfected with various con-
structs, and were subjected to microscopy (FRET, FLIM)
analyses. To evaluate the effect of GSMs on APP, the
cells were treated for 24 hours with either 100 μM feno-
fibrate or 400 μM ibuprofen. To inhibit the interaction
between APP and PS1/g-secretase, cells were treated for
24 hours with 100 nM helical peptide (a gift from Dr.
M. Wolfe, BWH, Boston, MA), which was designed to
mimic a portion of the APP transmembrane domain
and competes with APP for binding to PS1/g-secretase
[34]. Control cells were treated with a vehicle (either
DMSO or ethanol).
Constructs
Human APP 695 isoform was tagged with either green
or red fluorescent protein at its C-terminus to generate
APP-GFP and APP-mRFP constructs, respectively. APP
mutations (V717I, V717K, I716F) were inserted using
Quick Change Site-Directed mutagenesis kit (Strata-
gene), according to the manufacturer’s instructions. GFP
with myristoylation signal at the N-terminus was
PS1 (wild-type)
PS1 (mutant)
PS1 (wild-type)
APP (wild-type)
APP (mutant)
APP (wild-type)
+
+
+
PS1 (“Open”: AE40 production)
PS1 (“Closed”: AE42 production)
B
C
A
Figure 4 A scheme of reciprocal interaction between APP-CT positioning relative to the membrane and PS1 conformation . Wild type
PS1/g-secretase can exist in an “open” and “close” conformational states that correlate with production of Ab40 and Ab42, respectively (Lleo,
2004, Berezovska 2005), with the “open” conformation being a predominant state (A). The C-terminus of APP bearing FAD mutation(s) associated
with the increased Ab42/40 ratio (orange/red) positions closer to the membrane (B), compared to that in the wild type APP (A). When
incorporated into wild type PS1/g-secretase, it can induce conformational change of PS1 by bringing PS1 NT and CT closer together [25]. On the
other hand, when wild type APP is incorporated into FAD-mutant PS1/g-secretase that predominantly exist in a “closed” conformation, the
position of APP C-terminus changes and comes closer to the membrane (C).
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tech, Madison, WI) was used as a control for expression
of EGFP without a membrane targeting signal. Wild-
type PS1, as well as E318G and G384A mutant PS1 con-
structs were described previously [27].
Fluorescence Lifetime Imaging Microscopy (FLIM)
FLIM was used as an approach to monitor proximity
between the myrGFP labeled membrane and APP-CT-
RFP. Briefly, cells expressing myrGFP only were used as a
negative control to determine the baseline myrGFP life-
time. The degree of GFP donor lifetime shortening due to
presence of FRET was used as an indicator of the proxi-
mity between the GFP donor and RFP acceptor fluoro-
phores in myrGFP and APP-RFP cotransfected cells. The
FLIM software uses the Levenberg-Marquardt algorithm
to fit the raw data from each pixel to two-exponential
fluorescence decay curves to record presence of a shorter
than baseline GFP lifetime (for details please see [24,27].
Alternatively, the plasma membrane was labelled with
CM-DiI (Molecular Probes) as an acceptor fluorophore
in the FLIM assay, and GFP-donor was fused to the
APP CT. In this case, cells expressing APP-CT-GFP but
not labelled with the CM-DiI served as a negative con-
trol. To label the membrane, cells were incubated with
1 μg/ml of CM-DiI dissolved in PBS for 15 minutes at
4°C and fixed with 4% paraformaldehyde, prior to the
FLIM analysis. Data analysis was performed using SPC
Image (Becker&Hickl, Berlin, Germany), in which donor
fluorophore lifetimes are determined by fitting the data
to one (negative control) or two (experimental condi-
tions) exponential decay curves. In two component ana-
lysis, GFP lifetime (negative control with no acceptor
fluorophore) is monitored first, and its value is “fixed”
as t1 lifetime. The second, shorter lifetime representing
FRET is calculated by the system as t2 value. This t2
value was used for comparisons between different
experimental conditions. Thus, “non-FRETing” compo-
nent (t1 lifetime representing APP molecules that do
not interact with PS1, and thus position in the mem-
brane in such a way that does not support FRET) is
excluded from the lifetime comparisons.
ELISA
To measure the effect of APP mutations on Ab produc-
tion, wild-type APP-RFP, or APP-RFP, with V717I,
V717K or I716F mutations were transfected into CHO
cells cultured in 35 mm dishes. 6 hours after the trans-
fection, culture medium was exchanged with 1 ml of
fresh OPTI-MEM with 1% FBS, and cells were grown
for an additional 24 hours. The conditioned medium
was subjected to ELISA analysis using human b-amyloid
(1-40 and 1-42) ELISA kit (WAKO, JAPAN), according
to the manufacturer’s instruction.
Statistical analysis
StatView for Windows, Version 5.0.1 (SAS Institute, Inc)
was employed to perform statistical analysis using Fish-
er’s PSLD analysis of variance (ANOVA). Samples were
considered significantly different at p < 0.05.
Additional material
Additional file 1: Inhibition of APP-PS1/g-secretase interaction, and
not the level of expression, alters APP-CT positioning to the
membrane. (Figure S1)- Level of expression of the wild type (wt), and
V717I, I716F and V717K APP mutants in APP/APLP2 dko cells. Level of
expression of the wild type APP-RFP (Figure S2) or PS1 (Figure S3) does
not alter APP C-terminus positioning relative to membrane, as detected
by the FLIM assay (graph in B and C). (Figure S4)- FLIM analysis of APP/
APLP2 dKO cells co-transfected with myrGFP and wild-type APP-RFP, and
treated with either DMSO or docking site g-secretase inhibitor, HP. The
lifetime of donor myrGFP was significantly longer in cells treated with
the HP, compared to that in cells treated with the DMSO (mean ± SD; *
p < 0.05, ANOVA). Results from three independent experiments are
shown. (n: number of cells examined.)
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